To evaluate the treatment effects of β-glucan contained in an extract from Saccharomyces cerevisiae (β-GESc) on tumor development in a B16F10 melanoma model, highlighting its potential as a therapeutic strategy.
Key Findings:
β-GESc treatment increased spleen size and splenocyte counts, including macrophages, dendritic cells, NK cells, and NKT cells.
Enhanced MHC class II expression by dendritic cells and promoted germinal center formation.
Increased monocyte and lymphocyte counts, improved survival rates, and reduced tumor growth.
Treated mice preserved spleen white pulp and expanded T-cell zones, while untreated mice showed tumor cell infiltration.
Higher absolute numbers of CD4+ and CD8+ T cells producing IFN-γ and TNF-α were observed after anti-CD3 stimulation.
Interpretation:
β-GESc demonstrates immunomodulatory potential, enhancing both splenic and systemic immune responses, which may contribute to improved control of experimental melanoma and warrant further investigation.
Limitations:
Study conducted in a mouse model, which may not fully replicate human responses; further studies are needed to validate findings in human subjects.
Long-term effects and mechanisms of β-GESc treatment require further investigation to understand its full therapeutic potential.
Conclusion:
β-GESc treatment shows promise as an immunomodulatory agent in controlling melanoma progression, suggesting potential for clinical application in melanoma therapy.
by Bruno Miranda dos Santos Oliveira, Fernanda Paloma Duarte Trierweiler, Bianca Ramos Mesquita, Jose Nathan Andrade Muller Da Silva, Washington Luís dos Santos, José Mengel, Fabíola Cardillo
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
